<DOC>
	<DOCNO>NCT00619216</DOCNO>
	<brief_summary>Liver transplant patient often require multimodal immunosuppressive therapy minimize risk rejection . In regimen , MMF ( mycophenolate mofetil ) often add low side effect calcineurin inhibitor . Unfortunately literature report 20 % many 40 % patient GI intolerance MMF . At Center , approximately 30 % patient intolerance MMF , thereby mitigate ability use agent . The primary objective study assess tolerability myfortic combination Neoral Tacrolimus determine GSRS ( Gastrointestinal Symptom Rating Scale ) conversion MMF maintenance liver transplant patient GI intolerance within 3 month .</brief_summary>
	<brief_title>Myfortic Conversion Trial OLT Recipients With GI Intolerance</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Recipients orthotopic liver transplant least 8 week post transplant Mild and/or moderate GI complaint directly relate MMF Multiorgan transplant recipient Evidence graft rejection within 14 day prior Baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Orthotopic Liver Transplant Recipients GI disturbance</keyword>
</DOC>